These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27500463)

  • 1. Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex
    Carotenuto A; Iodice R; Petracca M; Inglese M; Cerillo I; Cocozza S; Saiote C; Brunetti A; Tedeschi E; Manganelli F; Orefice G
    Acta Neurol Scand; 2017 Apr; 135(4):442-448. PubMed ID: 27500463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
    J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
    Freidel M; Tiel-Wilck K; Schreiber H; Prechtl A; Essner U; Lang M
    Acta Neurol Scand; 2015 Jan; 131(1):9-16. PubMed ID: 25208898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
    Leocani L; Nuara A; Houdayer E; Schiavetti I; Del Carro U; Amadio S; Straffi L; Rossi P; Martinelli V; Vila C; Sormani MP; Comi G
    J Neurol; 2015 Nov; 262(11):2520-7. PubMed ID: 26289497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.
    Lu L; Pearce H; Roome C; Shearer J; Lang IA; Stein K
    Pharmacoeconomics; 2012 Dec; 30(12):1157-71. PubMed ID: 23072659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
    Collin C; Ehler E; Waberzinek G; Alsindi Z; Davies P; Powell K; Notcutt W; O'Leary C; Ratcliffe S; Nováková I; Zapletalova O; Piková J; Ambler Z
    Neurol Res; 2010 Jun; 32(5):451-9. PubMed ID: 20307378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study.
    Russo M; De Luca R; Torrisi M; Rifici C; Sessa E; Bramanti P; Naro A; Calabrò RS
    Eur Rev Med Pharmacol Sci; 2016 Jul; 20(14):3127-33. PubMed ID: 27460745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
    Patti F; Messina S; Solaro C; Amato MP; Bergamaschi R; Bonavita S; Bruno Bossio R; Brescia Morra V; Costantino GF; Cavalla P; Centonze D; Comi G; Cottone S; Danni M; Francia A; Gajofatto A; Gasperini C; Ghezzi A; Iudice A; Lus G; Maniscalco GT; Marrosu MG; Matta M; Mirabella M; Montanari E; Pozzilli C; Rovaris M; Sessa E; Spitaleri D; Trojano M; Valentino P; Zappia M;
    J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):944-51. PubMed ID: 27160523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).
    Messina S; Solaro C; Righini I; Bergamaschi R; Bonavita S; Bossio RB; Brescia Morra V; Costantino G; Cavalla P; Centonze D; Comi G; Cottone S; Danni MC; Francia A; Gajofatto A; Gasperini C; Zaffaroni M; Petrucci L; Signoriello E; Maniscalco GT; Spinicci G; Matta M; Mirabella M; Pedà G; Castelli L; Rovaris M; Sessa E; Spitaleri D; Paolicelli D; Granata A; Zappia M; Patti F;
    PLoS One; 2017; 12(8):e0180651. PubMed ID: 28763462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
    Paul F; Silván CV
    Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.
    Russo M; Calabrò RS; Naro A; Sessa E; Rifici C; D'Aleo G; Leo A; De Luca R; Quartarone A; Bramanti P
    Neural Plast; 2015; 2015():656582. PubMed ID: 25699191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    Trojano M; Vila C
    Eur Neurol; 2015; 74(3-4):178-85. PubMed ID: 26571097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.
    Giacoppo S; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2017 Oct; 17():22-31. PubMed ID: 29055461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
    Flachenecker P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
    Meuth SG; Vila C; Dechant KL
    Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.